openPR Logo
Press release

Candidiasis Therapeutics - Clinical Trials & Results and Key Players Analysis SCYNEXIS, Inc., Matinas BioPharma

12-13-2018 05:51 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: P&S Intelligence

Candidiasis Therapeutics - Clinical Trials & Results and Key

The study analyzed that the candidiasis therapeutics pipeline comprises approximately 22 drug candidates in different stages of development.

Download free report sample at: https://www.psmarketresearch.com/market-analysis/candidiasis-therapeutics-pipeline-analysis/report-sample

*Cochleate technology platform for Candidiasis drug development

Matinas Biopharma Holdings, Inc. is using Cochleate technology platform for the development of their drug candidates. The technology platform is a lipid-crystal nano-particle targeted drug delivery system, that offers a drug delivery solution with differentiating and disruptive features including oral availability, multi-organ protection, enhanced safety and targeted delivery to the site of the infection and inflammation along with the ability to effectively penetrate the tissues.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=candidiasis-therapeutics-pipeline-analysis

*Ample Designations from the U.S. Food and Drug Administration (USFDA) to the market players manufacturing drugs for Candidiasis

The research found that various companies received many designations from the U.S. Food and Drug Administration (USFDA) for the development of candidiasis therapeutics pipeline. In May 2016, USFDA granted the orphan drug designation to SCY-078 for the treatment of invasive candida infections, including candidemia.

Browse report at: https://www.psmarketresearch.com/market-analysis/candidiasis-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of candidiasis include Seren Pharmaceuticals, Inc., SCYNEXIS, Inc., Matinas Biopharma Holdings, Inc., and others.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Candidiasis Therapeutics - Clinical Trials & Results and Key Players Analysis SCYNEXIS, Inc., Matinas BioPharma here

News-ID: 1436841 • Views:

More Releases from P&S Intelligence

U.S. ESG Investments Market Set to Skyrocket: $16 Trillion by 2032
U.S. ESG Investments Market Set to Skyrocket: $16 Trillion by 2032
According to the latest market research study published by P&S Intelligence, the U.S. Environmental, Social, and Governance (ESG) investments market is experiencing a significant surge, with projections indicating an increase from $6.5 trillion in 2024 to an estimated $16.0 trillion by 2032. This represents a robust compound annual growth rate (CAGR) of 12.1% over the forecast period. According to a comprehensive analysis by P&S Intelligence, the market's expansion is driven
Facility Management in the U.K. Booms with 14.1% CAGR as Demand Soars Across Sectors
Facility Management in the U.K. Booms with 14.1% CAGR as Demand Soars Across Sec …
According to the latest market research study published by P&S Intelligence, the U.K. facility management market is poised for significant growth, with projected revenues reaching USD 2,743.3 million in 2024 and expected to soar to USD 6,038.4 million by 2030, reflecting a robust CAGR of 14.1% during the forecast period. This expansion is fueled by a surge in demand across both public and private sectors. According to the RICS U.K.
Point-of-Sale Software Market in the U.S. Set to Grow by 9.7% CAGR, Boosted by Omnichannel Integration
Point-of-Sale Software Market in the U.S. Set to Grow by 9.7% CAGR, Boosted by O …
According to the latest market research study published by P&S Intelligence, the U.S. point-of-sale (POS) software market, valued at USD 4.7 billion in 2024, is poised for significant growth over the coming years, with projections estimating it will reach USD 9.8 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.7%. This growth is attributed to rapid technological advancements, a surge in mobile and cloud-based POS systems,
Competitive Landscape of the Industrial Starches Market: Key Players, Trends, and Growth Opportunities
Competitive Landscape of the Industrial Starches Market: Key Players, Trends, an …
According to the latest market research study published by P&S Intelligence, the global industrial starches market is poised for significant growth, with a projected increase from USD 110.3 billion in 2024 to USD 169.9 billion by 2030, at a robust compound annual growth rate (CAGR) of 7.5%. Industrial starches play a crucial role in diverse sectors, including food, pharmaceuticals, and paper, driven by their unique properties such as stabilizing, thickening,

All 4 Releases


More Releases for Candidiasis

Rising Fungal Infection Rates Fueling Growth In The Candidiasis Therapeutics Mar …
The Candidiasis Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Candidiasis Therapeutics Market Size and Projected Growth Rate? Recent years have seen consistent growth in the size of the market for candidiasis therapeutics. This is predicted to further expand from $3.19 billion
Acute Vulvovaginal Candidiasis Market Beyond Douching: New Treatment Options Dri …
Acute Vulvovaginal Candidiasis Market worth $ 485.54 Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Acute Vulvovaginal Candidiasis Market- by Drug Type (Clotrimazole, Nystatin, Fluconazole, , Terbinafine, Terconazole and Other Drug Types), Route of Administration (Oral, Intravenous and Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Trends, Industry Competition Analysis, Revenue and Forecast
Vulvovaginal Candidiasis Market to Witness Robust Expansion by 2029
This comprehensive report thoroughly assesses various regions, estimating the volume of the global Vulvovaginal Candidiasis market within each region during the projected timeframe. The report is meticulously crafted and includes valuable information on the current market status, historical data, and projected outlook. Furthermore, it presents a detailed market analysis, segmenting it based on regions, types, and applications. The report closely monitors key trends that play a crucial role in determining
Recurrent Vulvovaginal Candidiasis Market - Defeating Recurrent Vulvovaginal Can …
Newark, New Castle, USA: The "Recurrent Vulvovaginal Candidiasis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Recurrent Vulvovaginal Candidiasis Market: https://www.growthplusreports.com/report/recurrent-vulvovaginal-candidiasis-market/8832 This latest report researches the industry structure,
Candidiasis Epidemiology Insights to 2025
Publisher " Candidiasis - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Candidiasis in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Candidiasis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with
Candidiasis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Candidiasis - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H1 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape. Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin